Withdrawing Drugs in the U.S. Versus Other Countries by Ninan, Benson & Wertheimer, Albert I
Volume 3 | Number 3 Article 87
2012
Withdrawing Drugs in the U.S. Versus Other
Countries
Benson Ninan
Albert I. Wertheimer
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87.
http://pubs.lib.umn.edu/innovations/vol3/iss3/6
Commentary POLICY 
 
http://z.umn.edu/INNOVATIONS                       2012, Vol. 3, No. 3, Article 87                           INNOVATIONS in pharmacy   1 
 
Withdrawing Drugs in the U.S. Versus Other Countries 
Benson Ninan, Pharm.D.
1
 and Albert I Wertheimer, PhD, MBA
2
 
1
Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 
2
Temple University School of Pharmacy, Philadelphia PA  
 
Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list 
 
Abstract 
Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries.  Interestingly, there are a 
number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products 
that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies 
for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries 
to use for local decision guidance. 
 
 
Background 
At present, one of the leading causes of death in the U.S. is 
believed to be adverse drug reactions.
1-14
 More than 20 
million patients have taken at least 1 of the 5 drugs 
withdrawn from the market between September 1997 and 
September 1998. Seven drugs that were approved in 1993 
and were withdrawn shortly later have contributed to 1002 
deaths.
14
 A study in 2002, showed that out of the 548 drugs 
that were approved in the U.S. between 1975-1999, fifty six 
(10.2 %) of them required a new black box warning or were 
withdrawn.
12 
Thus, it is very important that the consumer as 
well as the practitioner become aware of dangerous drugs.   
 
In 1979 the United Nations General Assembly first brought up 
the question of establishing a list of banned pharmaceutical 
products that could be exchanged between nations. Under 
resolution 37/137 (Annex I) of December 17 1982, the 
General Assembly requested the Secretary-General to 
organize the Consolidated List of Products Whose 
Consumption and/or Sale Have Been Banned, Withdrawn, 
Severely restricted or Not Approved by Governments. The List 
is a continuing effort by the United Nations to circulate 
information on products that are harmful to health and the 
environment.
2
 
 
 
The first issue of the List covered less than 500 products 
regulated by 60 governments. The fifth issue which covered 
both pharmaceuticals and chemicals, included over 700 
products regulated by 94 governments. By the eleventh and 
twelfth editions, the List had grown to include more than  
1100 products regulated by 115 states.
2
 At present the most  
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recently updated issue is the fourteenth issue, which contains 
data on 66 new products with updated/new information on 
22 existing products. An update of the fourteenth issue was 
published in 2010 adding 99 more products to the List by the 
actions of 38 governments.
3
  
 
 In 1985 the United Nations Secretariat, in conjunction with 
the World Health Organization (WHO) and the United Nations 
Environment Program (UNEP) met at the first inter-agency 
meeting and executed the first review of the List. The review 
outlined key points such as arrangements for the preparation 
of future issues, the need for criteria for determining the 
inclusion of products, the question of the legal and public 
health context of regulatory actions that were not included in 
the first issue of the List and the treatment of commercial 
data.
2
 Ever since then the List has been updated annually 
making the information available to users through direct 
internet access.  
 
Introduction 
Since 1995 the List was divided into two separate issues, one 
focusing on pharmaceuticals and the other on chemicals, 
which are published in alternate years. The pharmaceuticals 
are further separated into monocomponent products, 
combination products and group products.
2
 This paper will 
only focus on the 151 monocomponent pharmaceuticals that 
were withdrawn and why they were withdrawn by the U.N. 
and by specific countries such as the USA, Japan, UK, Sweden 
and Australia. 
 
More specifically, this paper will compare the drugs banned 
in the U.S. versus the drugs banned in other prominent 
countries. Do we have similar policies on which drugs to 
withdraw or, does the U.S. act on its own when it comes to 
drug withdrawal?  
 
While the U.N. may outlaw a certain drug, it is possible that 
the banned drug may be still available in certain countries. In 
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addition, this paper will investigate any lag time that may 
occur between the issue date of withdrawal by the U.N. and 
the actual date it was removed from the specific country. It is 
important to note that if a product is not listed as regulated 
by a country it does not necessarily mean that it is permitted 
in the country. It is highly possible that some information has 
not been communicated to the U.N.
2
 as well. 
 
Drugs Banned in the U.S.  
In the United States of America, The Center for Drug 
Evaluation and Research (CDER) a part of the U.S. Food and 
Drug Administration (FDA) is in charge of evaluating new 
drugs for safety and effectiveness before they may be sold. 
After the drugs are on the market, CDER acts as a watchdog, 
monitoring for any side effects and for any unexpected health 
risks. Sometimes drugs have to be withdrawn from the 
market due to severe unwanted side effects that may be 
fatal. In 2005, new molecular entities (NME) such as 
valdecoxib, pemoline, and technetium (99m Tc) fanolesomab 
were all removed due to increased risk of serious adverse 
effects. Valdecoxib, a COX-2 selective inhibitor was removed 
from the market due to increased risk of skin reactions and 
cardiovascular events. Likewise pemoline, a CNS stimulant 
used for treatment of ADHD was removed because of fatal 
hepatoxicity
2
 (See appendix for more drugs that were 
removed in the U.S., Internationally, and worldwide). 
 
Figure 1 shows the percentage of the 151 drugs we studied 
that were removed in the U.S. compared to the drugs that 
were removed internationally and worldwide.   
 
Figure 1. 
 
 
 
Only 67 % of the 151 drugs that were on the List were banned 
by the U.S, while internationally 79 % were banned. This 
shows clearly that the U.S is not in complete agreement with 
the other countries on which drugs should be banned. There 
are many reasons why the policies of the U.S may differ from 
the international world. One reason might be a monetary 
benefit that drug companies/ government get from keeping a 
drug on the market. An example of a drug that has continued 
to be kept on the market is the anti-diabetic drug, 
rosiglitazone (Avandia). A drug might also be kept on the 
market in one country because it has a legitimate medical 
use, while in another country it may not be used medically 
and therefore is banned. For example, flunitrazepam, 
commonly known as the date rape drug “roofies”, is used for 
the treatment of insomnia in many European countries. 
However, the FDA has not approved the use of flunitrazepam 
and it has deemed it an illegal substance.
2 
 
Figure 1 also shows that only 19% of drugs were banned 
worldwide.  This shows the lack of agreement on which drugs 
should be banned globally. It seems as if drugs that were 
banned worldwide had to have severe fatal adverse effects 
before they reached the eyes of the entire world. Drugs such 
as Fen-Fen which contained fenfluramine and phentermine 
were mainly removed after 20 years in the U.S. market due to 
a lawsuit which totaled over $13 billion in legal damages and 
of course potential fatal pulmonary hypertension and heart 
valve problems.
10
 Both fenfluramine and its d-enantiomer, 
dexafluramine (Redux) were withdrawn in September 1997 
worldwide. The second drug that made up Fen-fen, 
phentermin was banned in Sweden and the United Kingdom 
in 1981 and 2000 respectively. However, it is still marketed 
widely in the U.S. 
2 
Figure 2.  
 
 
  
Figure 2 compares the drugs that were banned in the U.S. but 
are available internationally versus the drugs that are banned 
internationally but are available in the U.S. It shows that 9 % 
of the drugs banned by the U.S. are available in the 
international market. On the other hand, of the drugs banned 
internationally, 17 % are available in the U.S. This goes to 
show again that the policies of the U.S. may tend to be 
different than the rest of the World. Of the 17 % 
internationally banned drugs, three of the drugs are from the 
same class of drugs, the barbiturates. In Sweden, barbiturates 
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such as amobarbital, hexobarbital, pentobarbital and 
phenobarbital were all banned due to fatal intoxications and 
abuse potential. In April 2001, France suspended the 
production of phenobarbital due to reports of rare but severe 
cutaneous and mucosal reactions including Steven-Johnson 
Syndrome and Lyell Syndrome.
2
 However, phenobarbital is 
still used vigorously in the U.S. for the treatment of epilepsy/ 
tonic-clonic seizures.  
 
Another drug that is widely used in the U.S., but is banned 
internationally is the muscle relaxant, carisoprodol (Soma). In 
November 2007, the European Medicines Agency (EMA) 
recommended the suspension of marketing authorization 
after evidence of abuse and addiction from taking 
carisoprodol for back pain. Both Norway and Sweden have 
pulled carisoprodol off the market due to problems of 
dependence and intolerable side effects. As of 2008, the UK 
had planned to pull carisoprodol off the market due to 
increased risk of abuse, addiction, intoxication, and 
psychomotor impairment.
1  
 
As of March 26 2010, the abuse potential of carisoprodol was 
brought to light in the U.S, as the DEA issued a Notice of 
hearing discussing the plan to place carisoprodol as a 
controlled substance. However, as of today carisoprodol is 
not a controlled substance under federal regulations while 
certain states consider it to be a controlled substance. These 
states include Alabama, Arizona, Arkansas, Florida, Georgia, 
Hawaii, Indiana, Kentucky, Louisiana, Massachusetts, 
Minnesota, Mississippi, New Mexico, Nevada, Oklahoma, 
Oregon and Texas.
4
 While it is not a controlled substance in 
many states carisoprodol is only approved for short term use 
and prescribers are encouraged not to prescribe the drug to 
people with a background of addiction. It is interesting to 
notice that cariosprodol’s metabolite, meprobamate which 
has significant anxiolytic properties was banned in Sweden in 
1981 due to potential for abuse and addiction.
2
 The UK was 
also planning to remove meprobamate due to severe side 
effects.
1
 In the U.S. it has been classified as C-IV and was the 
best-selling tranquilizer for a long time before being replaced 
by the benzodiazepines.  
 
A very controversial drug that has caused 13,000 lawsuits, 
while bringing in annual sales peaking at approximately $2.5 
billion for GlaxoSmithKline in 2006, was the antidiabetic drug, 
rosiglitazone (Avandia). Rosiglitazone has been associated 
with increased risk of heart failure by 64 % over a seven year 
period.
7
 In September 2010, the EMA suspended the drug 
from the European market completely.
 5
 The U.S. however, 
continues to market the drug with a black boxed warning.   
 
Only 9% percent of drugs banned by the U.S. are available 
internationally as shown in Figure 2. In November 2000, the 
FDA issued a public health advisory against the use of 
phenylpropanolamine, a psychoactive drug used as a 
stimulant, decongestant, and anorectic. Due to increased risk 
of strokes in young women, FDA requested the suspension of 
marketing of this drug and removed phenylpropanolamine 
from all OTC formulations in 2005.
11
 While Canada has also 
withdrawn the drug, Europe continues to market it as a 
prescription and OTC drug. In the UK, it is sold in 
combinations with acetaminophen and caffeine as a cough 
and cold medication.   
 
Another drug that has been banned in the U.S. but is 
available outside the U.S is pergolide (Permax), a dopamine 
receptor agonist used for the treatment of Parkinson’s 
disease. Permax was approved in 1988 as an adjunctive 
therapy with levodopa in Parkinson's disease. Valvular heart 
disease was first described in association with pergolide in 
2002. In 2003, the FDA asked Lilly to add valvulopathy 
(abnormality of cardiac valves) to the warnings section of 
Permax labeling. In 2006, the warning was upgraded to a 
black box warning, the FDA's strongest form of warning, 
because of new data concerning risks of heart valve damage. 
In 2007, it was removed from the U.S market due to 
increased rates of vavular dysfunction that were associated 
with using the drug. Pergolide is still used in other countries 
such as the UK and Australia for the treatment of Parkinson’s 
disease, hyperprolactinemia and restless leg syndrome.
8 
 
Figure 3.  
 
 
 
Figure 3 shows the percentage of the 151 drugs we studied 
that were banned in the U.S. first versus the percentage of 
drugs banned first in the other countries (UK, Australia, 
Sweden, and Japan). Approximately 36 % of the drugs banned 
were first banned internationally before they were banned in 
the U.S. Only 21 % of the drugs were banned by the U.S. first 
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before they were also banned by the rest of the world. For 
the remaining 43%, differences were not detected. This 
shows that the U.S. may no longer be leader in observing, 
reporting and removing dangerous drugs from the market. 
This might be because the drug might have been introduced 
first internationally before it became available in the U.S. 
Thus, the time for the FDA to see any adverse effects from 
the drug might have lagged in comparison to other countries.  
For example, troglitazone, a thiazolidinediones used to treat 
diabetes was first introduced by a Japanese company. Due to 
an idiosyncratic reaction leading to hepatitis it was only 
approved in January 1997 in the U.S. However, it was already 
on the world market years before and was voluntarily 
removed in December 1997 in the UK and Japan due to 
concerns of hepatotoxicity.
2
 Since the U.S. was late to 
approve the drug, logically they were only able to withdraw 
the drug by 2000. 
 
Another drug that the U.S. was slow in removing from the 
market was the well known prescribed pain killer, 
dextropropoxyphene also called as propoxyphene (Darvon-
N). This drug was usually combined with acetaminophen 
under the brand, Darvocet. Dextropropoxyphene which has 
been on the marker for more than 25 years came under fire 
in 1978 by consumer groups who claimed it caused suicides in 
many of the patient. The manufacturing company, Eli Lilly 
minimized the news and persuaded doctors that 
dextropropoxyphene was safe as long it was not mixed with 
alcohol. In 2004, products containing only 
dextropropoxyphene were removed in U.K. and later in June 
2009, the EMEA recommend gradual withdrawal of all 
products containing dextropropoxyphene from the European 
Union.
6 
 
A month later in the U.S., the FDA still decided to continue 
marketing dextropropoxyphene with a black box warning for 
the risk of overdose. On November 19 2010, the FDA finally 
pulled all forms of dextropropoxyphene from the market due 
to risk of heart arrhythmias. It is alarming that a drug such as 
dextropropoxyphene that had a high potential risk of causing 
heart problems was on the market for more than 20 years 
before it was completely removed. It is estimated that over 
10 million people may have used these products.
9 
 
Conclusion                                                                                                                            
Drug withdrawal is an important task that involves continued 
surveillance and pharmacovigilance and is as important as the 
process of drug discovery and production. Since the 
establishment of the List, the dissemination of information on 
which drugs are banned has become easier. Nevertheless, 
countries tend to have different policies on which drugs to 
withdraw and when to withdraw them. The U.S. is on its own 
time course compared to other countries such as UK, Japan, 
Australia and Sweden and withdraws drugs based on the 
FDA’s decisions. Likewise in order for a drug to be withdrawn 
globally, the side effects usually have to be severe enough to 
catch the attention of the entire world. In addition most of 
the time, drugs are kept on the market for many years before 
they are found to be more harmful than good. While there 
might be monetary benefits for each country in keeping these 
drugs on the market, the U.N. must step up the visibility of 
the withdrawal of dangerous drugs list. 
 
References  
1. "Carisoprodol and meprobamate: risks outweigh 
benefits." Drug Safety Update. MHRA, 03 Sept 2010. 
Web. 22 Jun 2011. 
http://www.mhra.gov.uk/Safetyinformation/DrugSaf
etyUpdate/CON084737. 
2. "Consolidated List of Products." World Health 
Organization. United Nations, 2005. Web. 22 Jun 
2011. 
http://apps.who.int/medicinedocs/documents/s167
80e/s16780e.pdf. 
3. "Consolidated List of Products Whose Consumption 
and/or Sale Have Been Banned, Withdrawn, Severely 
Restricted or not Approved by Governments." United 
Nations. United Nations, 2009. Web. 22 Jun 2011. 
http://www.un.org/esa/coordination/CL-14-
Final.for.Printing.pdf. 
4. "Drugs and Chemicals of Concern: Carisoprodol." 
Office of Diversion Control. DEA, June 2009. Web. 22 
Jun 2011. 
http://www.deadiversion.usdoj.gov/drugs_concern/
carisoprodol.htm. 
5. "European Medicines Agency recommends 
suspension of Avandia, Avandamet and Avaglim." 
European Medicines Agency. EMEA, 2011. Web. 23 
Jun 2011. 
http://www.ema.europa.eu/ema/index.jsp?curl=pag
es/news_and_events/news/2010/09/news_detail_0
01119.jsp&murl=menus/news_and_events/. 
6. "European Medicines Agency (EMEA) recommends 
withdrawal of dextropropoxyphene-containing 
medicines ." MHRA. MHRA, 25 June 2009 . Web. 23 
Jun 2011. 
http://www.mhra.gov.uk/NewsCentre/CON049300. 
7. "Ex-Regulator Said to Testify GlaxoSmithKline 
Withheld Study." Bloomberg Businessweek 10 July 
2010:  23 Jun 2011. 
http://www.businessweek.com/news/2010-07-
10/ex-regulator-said-to-testify-glaxosmithkline-
withheld-study.html. 
Commentary POLICY 
 
http://z.umn.edu/INNOVATIONS                       2012, Vol. 3, No. 3, Article 87                           INNOVATIONS in pharmacy   5 
 
8. "FDA Announces Voluntary Withdrawal of Pergolide 
Products Agency Working with Product 
Manufacturers." FDA. FDA, 29 March 2007.Web.  23 
Jun 2011.  
http://www.fda.gov/newsevents/newsroom/pressa
nnouncements/2007/ucm108877.htm. 
9. "FDA pulls common pain med off the market." CNN 
19 November 2010:  Web. 23 Jun 2011. 
http://www.cnn.com/2010/HEALTH/11/19/fda.remo
ves.drug/. 
10. "Fen-Phen Case Lawyers Say They'll Reject Wyeth 
Offer." New York Times (2005):  22 Jun 2011. 
http://query.nytimes.com/gst/fullpage.html?res=95
05E7D6133AF934A25751C0A9639C8B63. 
11. " Information by Drug Class Drug Safety and 
Availability Information by Drug Class - FDA Letter to 
Manufacturers of Drug Products Containing 
Phenylpropanolamine (PPA)." FDA. FDA, 3 November 
2000. Web. 23 Jun 2011. 
http://www.fda.gov/Drugs/DrugSafety/Informationb
yDrugClass/ucm150774.htm. 
12. Lasser, Karen, Paul Allen, and Steffie Woolhandler. 
"Timing of New Black Box Warnings and Withdrawals 
for Prescription Medications." JAMA. 305.24 (2002): 
2493. 
13. "Withdrawn List." FDA. FDA, n.d. Web. 22 Jun 2011. 
http://www.fda.gov/ohrms/dockets/ac/98/briefingb
ook/1998-3454B1_03_TOC.htm. 
14. Wood AJ. The safety of new medicines: the 
importance of asking the right questions. JAMA. 281 
(1999): 1753-1754. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commentary POLICY 
 
http://z.umn.edu/INNOVATIONS                       2012, Vol. 3, No. 3, Article 87                           INNOVATIONS in pharmacy   6 
 
Appendix: Drugs Banned in the U.S., Internationally, and Worldwide
Drugs Banned in U.S. 
Effective 
Date 
Drugs Banned 
But Available in 
U.S. 
Banned in 
other 
Countries 
(UK, 
Sweden, 
Japan, 
Australia) 
 
Effective 
Date 
Grounds for Removal 
Acetanilide   JPN 
 
Jul 1971 Aplastic anaemia 
Acetylfuratrizine   JPN Jul 1977 Superseded by safer and more 
effective preparations. 
Alclofenac   UK 
 
1979 Skin rashes and mutagenic activity  
Amfepramone   SWE 
 
Jan 1981 Potential for abuse 
Amfepramone HCl   UK 
 
Apr 2000 Risks outweigh benefits 
Amfetamine 1973    High risk of abuse and 
dependence 
Aminoglutethimide 1966    Serious toxic effects to thyroids, 
ovaries, adrenals and uteri of 
female rats  
caused sexual precocity and 
masculinization of young females 
Aminophenazone Nov 1977  AUS, JPN, 
UK 
SWE 
1965,  
Dec 1977, 
1989 
Importation inhibited due to bone 
marrow suppression and fatal 
agranulocytosis  
Not known if marketed in U.S.  
Amilprilose Jan 1994  
 
  Lack of efficacy and safety 
Amobarbital   SWE 
 
July 1985 Fatal intoxications and abuse 
Aphrodisiac drugs Jan 1990    Unsafe and of doubtful 
effectiveness 
Aprobarbital   SWE 
 
July 1985 Fatal intoxications and abuse 
Aristolochia   UK July 1999 End-stage renal failure  
 
  Aristolochic Acid UK, AUS Sept 2004 Nephrotoxic and carcinogenic  
 
Astemizole  
 
1999    QT prolongation 
Azaribine Aug 1976  
 
  Thromboembolism 
Benzylpenicillin sodium (topical) Feb 1972    Lack of effectiveness compared to 
risk  
Benoxaprofen 1982     
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Bithionol Oct 1967  JPN July 1971 Photosensitivity and cross-
photosensitivity with other 
chemicals 
Boric acid and borates (topical 
use in infants) 
1985  UK 
JPN 
 
July 1985 
Dead in infants 
Bromfenac Jun 1998  
 
  Hepatic failure 
Bromocriptine Sep 1989    Risk of rebound effect and only 10 
% benefit therapeutically 
Bunamiodyl 1964  SWE 1964 Repeat doses may be associated 
with oliguria, renal tubular 
necrosis, and death 
Calamus Nov 1968  
 
  Animal carcinogenicity 
Cerivastatin Aug 2001  Worldwide Aug 2001  Increased risk of rhabdomyolysis 
especially when used with 
gemifibrozil 
Chloroform Jul 1976  
 
JPN,UK May 1976 Liver cancer in mice and rats 
Cisapride Apr 2000  UK, JPN Jul 2000,  
Oct 2000,  
Dec 2002 
Cardiac events 
Clioquinol Nystaform 
removed 
(Clioquinol 
& nystatin) 
 JPN, SWE Sep 1970,  
Jun 1975 
 Causes subacute myelo-optic 
neuropathy (SMON) 
Cobalt (non-radioactive forms) Jul 1967    Lack of effectiveness in treating 
iron deficiency anemia and causes 
severe toxicity 
Coumarin   AUS Aug 15 1996 Death from hepatotoxicity in 
women  
Cyclandelate Dec 1996  
 
  Not effective vasodilator  
Dalkon shield 1974  UK 
 
1985 Increase risk of PID 
Dantron Mar 30 
1987 
 JPN, UK Feb 1987, 
Apr 1987-
May 2000 
Carcinogenic and genotoxicity  
Dexamfetamine 1973    Abuse and high risk of 
dependence 
Dexfenfluramine 
hydrochloride/Fenluramine 
Sept 1997  Worldwide  Heart valve problems and 
pulmonary hypertension  
Dibenzepin hydrochloride   SWE 
 
Jan 1983 Fatal suicidal attempts 
Diethylaminoethoxyhexestrol   JPN 
 
Dec 1970 Liver toxicity  
Difurazone   JPN Jul 1977 Superseded by safer and more 
effective products 
 
Dihydrostreptomycin Sep 1970  
 
  Otoxicity  
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Dihydroxymethylfuratrizine   
 
JPN July 1977 Superseded by safer and more 
effective products 
Dilevalol Aug 9 1990  
 
JPN Aug 9 1990 Worldwide removal- Liver toxicity  
Dimazole Jul 1977    Neurotoxic –avaliable in 40 
countries 
Dinoprostone   UK July 19 1990 Uterine hypertonia and foetal 
distress 
Domperidone(injectable) Jan 31 
1985 
 All Jan 31 1985 Worldwide removal-cardiotoxicity 
Droperidol   UK 
 
Mar 2001 Cardiac events 
Droxicam   E.U. Dec 14 1994 Suspended marketing 
authorization due to hepatic 
damage 
Ephedra Jan 02  
2004 
   Heart attack and stroke 
Erythrityl tetranitrate 1998    Lack of efficacy for management, 
prophylaxis or treatment of angina 
Erythromycin estolate   SWE  Severe cholestatic hepatitis and 
jaundice 
Ethyl nitrite (spirit) Jun 26 
1980 
   Risk of fatal 
methaemoglobinaemia and 
poisoning in some infants 
Factor IX   SWE 1984 Reports of infections with HIV (the 
AIDS virus) in patients treated 
with drug 
Factor VIII   UK Oct 1986 Reports of infections with HIV (the 
AIDS virus) in patients treated 
with drug 
Fenclofenac 1980s  UK 1985 Fatal  skin 
Rashes 
Feprazone   UK Mar 30 1984 Concern of risk/benefit ratio- only 
available in 7 countries 
Flosequinan October 
1993 
 UK Jul 1993 Increased hospitalization and 
death 
Flunitrazepam Not 
approved 
by FDA-
illegal drug 
 Available in 
other 
countries 
for 
treatment 
of 
insomnia 
  
Furazolidone 1991  Japan Jul 1977 Superseded by 
safer and more effective 
preparations 
Glafenine   E.U. 
Worldwide 
Jan 14 1992, 
May 1992 
Risk of serious anaphylactic 
reactions 
Grepafloxacin hydrochloride Oct. 27, 
1999 
 UK 
Worldwide 
Oct 1999 Cardiac arrhythmias; QT 
prolongation 
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Guanofuracin N/A  JPN Jul 1977 Superseded by safer and more 
effective preparations. 
Halogenated salicylanilides Dec 1 1975  JPN Jan 1976 Disabling skin disorders and 
photosensitivity in humans. 
Heptabarb   SWE 
 
Jul 1984 Fatal intoxication and abuse 
  Hexachlorophene JPN Mar 1972 Banned in nursing powder 
preparations due to brain edema. 
Carcinogenic? 
Hexobarbital   SWE 
 
Oct 1984 Fatal intoxication and abuse 
Hyoscine methonitrate   SWE Jun 1981 Removed from appetite 
suppressant forumulations 
Indoprofen 1984  UK 
Worldwide 
removal 
Dec 1983, 
1984 
Severe GI reactions 
 
Carcinogenicity in rats 
Iodinated casein strophanthin 
(neo-barine) 
Oct 1964    Thyrotoxic side effects 
Isocarboxazid   JPN Nov 1974 Lack substantial evidence of 
efficacy and safety 
Isoxicam 31 Oct 
1985 
 Worldwide  Fatal skin reactions 
Laetrile 24 Mar 
1987 
 AUS Feb 20 1986 Importation of drug prohibited 
due to lack of efficacy and toxicity; 
can be potentially fatal 
Levacetylmethadol 23 Aug 
2003 
 E.U. 2001 Pro-arrhythmic potential 
Levamfetamine 1973    Evidence of abuse and high risk of 
dependence 
Loperamide (Drop formulations) 1990  All 1990 Worldwide removal due to cases 
of paralytic ileus  
L-Tryptophan Nov 17 
1989 
 UK,SWE, 
JPN 
Dec 1989 
May 1990 
Eosinophilia-myalgia syndrome 
Lynestrenol 1970  
 
AUS 1980 Mammary tumours in the beagles 
Mephenesin   JPN Jul 1976 Lack of substantial evidence of 
efficacy and safety. 
Meprobamate   SWE Jan 1981 Potential for abuse and lack of 
effiacy 
Metamizole sodium Jun 27 
1977 
 AUS 
SWE 
1965, 
1999 
Prohibited the importation; fatal 
agranulocytosis 
Methapyrilene 1992  UK,AUS 
 
1979,  
1980 
Carcinogenicity in rodents 
Methiodal sodium   SWE Jan 1975 Induced muscle spasms, safer 
alternates available 
Metofoline Mar 1965  Not 
available 
outside 
U.S. 
 Eye changes and corneal opacities 
in dogs 
Metrodin HP   UK Feb 2003 Creutzfeldt-Jakob Disease 
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Mibefradil 1998  
 
UK Jul 1998 Numerous drug interactions 
Nebacumab 1993  Worldwide 
 
 Increased mortality  
Nialamide   JPN Nov 1974 Lack substantial evidence of 
efficacy and safety 
  Nifedipine AUS Mar 1996 10 mg withdrawn due to serious 
adverse effects related to rapid 
release and higher peaks. 
Committee has deferred ruling on 
5 mg for 12 months 
Nitrendipine   AUS  Registration refused on grounds of 
inadequate data on 
pharmacokinetics 
Nitrofural   JPN Jul 1977 Superseded by safer and more 
effective preparations 
Nomifensine Jan 1986  Worldwide  Haemolytic anaemia 
 
Noscapine   UK 
 
1991 Cough mixtures containing 
noscapine were withdrawn and all 
other noscapine products were 
placed under Rx only due to 
concerns of genotoxicity  
Oxyphenbutazone   SWE, UK Jan 1985 Blood dyscrasias. All products in 
UK have been revolved except eye 
ointment 
Oxyphenisatine acetate Feb 1972  AUS, JPN, 
UK 
1972,  
1978 
Fatal liver disease, jaundice 
UK-all removed except 
suppositories for single-dose use 
Pentobarbital   SWE 
 
Jul 1985 Fatal intoxications and abuse 
Pexiganan Mar 2000  
 
  Not approved-lack of efficacy  
Phenacetin Nov 1983  UK,SWE,JP
N, 
Mar 1980,  
Jul 1982,  
Aug 1982 
Carcinogenicity and renal damage, 
hemolytic anemia, 
methaemoglobinaemia 
Phenformin Nov 1978  SWE,UK Oct 1978, 
1982 
Severe lactic acidosis 
  Phenobarbital SWE Jul 1985 Abuse potential and fatal 
intoxication 
Phenolphthalein   European 
Union, JPN 
Dec 1997,  
Jan 1998 
skin reactions, potassium loss and 
atonia 
  Phentermine SWE,UK Jan 1981, 
 Apr 2000 
Potential for abuse; risk outweighs 
benefit 
Phenylpropanolamine Nov 2000    Hemorrhagic stroke; JPN, UK 
evidence is weak but package 
includes new warnings 
Pipamazine Jul 1969    Lack of proof of efficacy and safety 
 
Piperazine   SWE 1983 Carcinogenic and mutagenic 
potential 
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Pirprofen Sep 30 
1990 
 Worldwide  Fatal liver toxicity  
Pituitary-chorionic gonadotropin 
(injectable 
Jul 1972    Risk of eliciting antibodies to 
animal protein, leading to allergic 
reactions 
Polidexide sulfate   UK 1977 
 
Oculo-mucocutaneous syndrome 
Polyoxyethylated castor oil Jun 1984  Worldwide  Severe anaphylactoid reactions 
and haematological changes 
including hyperlipidaemia, altered 
blood viscosity and erythrocyte 
aggregation 
Practolol   SWE, 
UK 
May 1975, 
1977 
Only IV preparation available 
others removed due to evidence 
of oculo-mucocutaneous 
syndrome 
Prasterone 1985    Lack of efficacy and safety of long-
term use 
Prenylamine 1989  Worldwide  Polymorphic ventricular 
tachycardia 
 
Pumactant   
 
UK Apr 2000 Higher mortality rate in neonates 
Pyrrolizidine   UK 
 
Mar 1993 Liver toxicity 
Remoxipride Mar 1994  Worldwide  
 
 Aplastic anaemia 
Sertindole   UK 
 
Dec 1998 Cardiac arrhythmias 
Somatropin (pituitary-derived) Aug 1985  UK May 1985 Reports of death from 
development of Creutzfeldt-Jakob 
disease 
Strychnine and salts   JPN 1987 No demonstrated therapeutic 
value 
 
Sulfamethizole   SWE Feb 1984 Adverse reactions and low sales; 
replaced by newer safer 
antibiotics 
Sulfamethoxypyridazine   SWE Feb 1984 Adverse reactions and low sales; 
renal toxicity, sometimes fatal 
exfoliative dermatitis and 
erythema multiforma, hemolytic 
anemia/aplastic anemia 
Sulfathiazole Sep 1970    Serious adverse reactions as listed 
above 
Suloctidil 1985  
 
Worldwide  Hepatitis 
Suprofen May 1987  Worldwide  Sales had diminished to point 
product was  no longer 
economically viable 
Commentary POLICY 
 
http://z.umn.edu/INNOVATIONS                       2012, Vol. 3, No. 3, Article 87                           INNOVATIONS in pharmacy   12 
 
 
Temafloxacin Jun 1992  Worldwide  Hypoglycaemia, haemolytic 
anaemia, renal failure, hepatitis 
and anaphylactic reactions 
Terconazole   SWE Jul 1991 Vaginal suppositories containing 
80 mg and 160 mg terconazole 
was withdrawn due to febrile 
reactions 
Terfenadine 1998     Associated with rare, but serious 
heart problems when taken with 
certain antibiotics and antifungals; 
JPN,UK available with warnings 
Terodiline 1992  Worldwide  Ventricular tachycardia, heart 
block and bradycardia associated 
Tetracycline (pediatric) Jan 1979  AUS 1991 Stain teeth and retard bone 
growth 
Thenalidine Jul 1958  UK, SWE, 
AUS 
1961, 
1976,1980 
Severe neutropenia 
Tienilic acid Jan 1980   
 
 Liver toxicity 
Tolcapone   EME,UK, 
AUS, 
Nov 1998, 
Feb 1999 
Hepatotoxic  
Tolrestat Nov 1996  Worldwide 
 
 Hepatic necrosis and death 
  Triazolam AUS 
JPN 
UK 
Apr 1986, 
Mar 1992, 
Jun 1993 
0.50mg and 0.25mg triazolam 
were not approved due to risk of 
adverse effects. 0.125mg 
triazolam were approved for the 
treatment of insomnia. 
 Dose should not exceed 0.5 mg. 
Reversible psychiatric adverse 
effects, particularly loss of 
memory and depression 
  Troglitazone UK, JPN Dec 1997 Severe hepatocellular damage, 
hepatic necrosis and 
hepaticfailure 
  Trovafloxacin 
mesilate 
EME May 1999 Marketing authorization 
suspended due to hepatic events 
Urethane Mar 1977  JPN 
 
Jul 1975 Carcinogenicity 
Vinarol and viga (dietary 
supplements) 
Apr 2003    Unlabeled presence of sildenafil 
Vinbarbital   
 
SWE Jul 1984 Fatal intoxications and abuse 
Zimeldine Jul 1983  Worldwide  Hypersensitivity reactions and 
neurological complications 
Zomepirac Mar 1983    Serious allergic reactions, 
including five deaths from 
anaphylaxis 
